Searle Daypro protected from ANDAs until October 1999 by provision in 1996 budget act.
Executive Summary
SEARLE DAYPRO PROTECTED FROM ANDAs UNTIL OCT. 29, 1999 under language included in the 1996 budget agreement (HR 3019) signed into law April 26. The legislation prohibits generic manufacturers from filing an ANDA for Searle's nonsteroidal anti-inflammatory agent Daypro (oxaprozin) until the two-year exclusivity extension expires.